Drug intelligence / Profile preview

Meilia Fuxin

Development stage: Unknown
Lead developer: Sichuan Good Doctor Panxi Pharmaceutical
Administration: Oral

Overview

Meilia Fuxin is a traditional Chinese medicine (TCM) oral solution developed by Sichuan Good Doctor Panxi Pharmaceutical for the prevention and treatment of radiation-induced oral mucositis (RIOM). It is currently being evaluated in a Phase 2 clinical trial (CTR20241453) in China, specifically targeting patients with head and neck cancer who are receiving radiotherapy with or without cisplatin-based chemotherapy. The drug is designed to alleviate the severity of mucosal damage and promote healing of the oral cavity during cancer treatment. As a TCM formulation, it likely functions through multi-target anti-inflammatory and tissue-regenerative pathways to protect the oral mucosa from radiation damage.

Brand names: Meilia Fuxin
Other names: Meilia Fuxin oral solution

Beyond the preview

Go deeper on Meilia Fuxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meilia Fuxin.

Explore the full profile